Synthesis and In vitro cytotoxic activity evaluation of (E)-16-(substituted benzylidene) derivatives of dehydroepiandrosterone

In the present study, a new series of cytotoxic 16-(substituted benzylidene) derivatives of dehydroepiandrosterone (DHEA) were synthesized and evaluated against three different cancer cell lines. The cytotoxic 16-(substituted benzylidene) derivatives of DHEA were synthesized via aldol condensation o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Daru 2013-05, Vol.21 (5), p.1-1
Hauptverfasser: Vosooghi, Mohsen, Yahyavi, Hoda, Divsalar, Kouros, Shamsa, Hashem, Kheirollahi, Asma, Safavi, Maliheh, Ardestani, Sussan Kabudanian, Sadeghi-Neshat, Sareh, Mohammadhosseini, Negar, Edraki, Najmeh, Khoshneviszadeh, Mehdi, Shafiee, Abbas, oumadi, Alireza
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In the present study, a new series of cytotoxic 16-(substituted benzylidene) derivatives of dehydroepiandrosterone (DHEA) were synthesized and evaluated against three different cancer cell lines. The cytotoxic 16-(substituted benzylidene) derivatives of DHEA were synthesized via aldol condensation of DHEA with corresponding benzaldehyde derivatives. The cytotoxic activity of synthesized derivatives was evaluated against three different cancer cells including KB, T47D and SK-N-MC cell lines by MTT reduction colorimetric assay. The results indicated that 16-(substituted benzylidene) derivatives of DHEA could be served as a potent anti-cancer agent. The 3-cholro benzylidene derivatives of DHEA was the most potent synthesized derivative especially against KB and T47D cell lines (IC... values were 0.6 and 1.7 ...M; respectively). The cytotoxic potential of novel benzylidene derivatives of DHEA is mainly attributed to the position and nature of the substituted group on the benzylidene pendant. (ProQuest: ... denotes formulae/symbols omitted.)
ISSN:1560-8115
2008-2231